Posted on 02 February 2015
Pfizer issued to Repligen a notice of termination for convenience under the License Agreement, dated December 28, 2012, by and between the Company and Pfizer for the development of compounds to treat spinal muscular atrophy (SMA).
|Searching for more deal information? Current Partnering offers the following options:|
- CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
- Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
- CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time
The termination of the License Agreement will become effective as of April 26, 2015.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2014
View: Top pharmaceutical companies
View: Top biotech companies
Reports: Browse our extensive deal making report portfolio